Attorney General Matthew J. Platkin of New Jersey urges residents to determine their eligibility for compensation related to purchases of particular generic drugs. This follows New Jersey’s participation with 50 states and territories in seeking preliminary approval for a $39.1 million settlement with Apotex, a generic drug manufacturer. The case addresses allegations of a conspiracy involving inflated drug prices and restricted competition.
This settlement, along with a prior $10 million settlement with Heritage Pharmaceuticals, resolves accusations that Apotex and Heritage partook in extensive conspiracies to manipulate prices and reduce competition. As per the settlement terms, both companies will support ongoing litigation against various corporate and individual defendants. They have also committed to implementing reforms aimed at ensuring compliance with antitrust laws.
Individuals who purchased a generic prescription drug between May 2009 and December 2019 are potentially eligible for compensation. To ascertain eligibility, they may contact 1-866-290-0182.
These settlements are part of a broader effort involving nearly all states and territories, with antitrust complaints filed beginning in 2016. The ongoing investigations have uncovered significant evidence of alleged collusion amongst industry competitors.
The complaints detail how industry executives met at social gatherings like dinners and golf outings to discuss and manipulate competitive practices. This included exchanges where executives joked about high expenses being covered by competitor companies.
The legal proceedings continue to involve a collaborative effort from multiple states, including Alaska, Arizona, California, and others, with New Jersey represented by Deputy Attorney General Yale A. Leber under Assistant Attorney General Brian F. McDonough.
